Recoverin-associated retinopathy: a clinically and immunologically distinctive disease.
OBJECTIVE
To compare the immune response to retinal antigens in a patient with a clinical condition resembling cancer-associated retinopathy with the immune responses of patients with other retinal degenerations or uveitis.


METHODS
Cellular and humoral immune responses to retinal S-antigen and recoverin were determined in one patient with disease resembling cancer-associated retinopathy, three patients with other retinal degenerations, and eight patients with uveitis.


RESULTS
A cellular immune response against recoverin was found only in the patient with the condition resembling cancer-associated retinopathy. Elevated levels of antibody against recoverin were found in this patient and in one of the three patients with a retinal degeneration, but in none of the eight patients with uveitis. In contrast, moderate lymphocyte responses to retinal S-antigen were found in most of the patients studied, and this response did not distinguish among the patient groups. Levels of serum antibodies against retinal S-antigen were also similar in all patients tested. Serum from the patient with disease resembling cancer-associated retinopathy produced strong immunostaining of the rods, cones, outer plexiform layer, and some cone bipolar cells, but serum from the patients with uveitis or other retinal degenerations did not show specific reactivity with the retina.


CONCLUSIONS
We propose that this immunologically and clinically distinctive condition be termed recoverin-associated retinopathy, and we suggest that a cellular immune response against recoverin may be a distinguishing feature of the disorder.
Whitcup
S M
SM
National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892-1863, USA. scottw@helix.nih.gov
Vistica
B P
BP
Milam
A H
AH
Nussenblatt
R B
RB
Gery
I
I
D000235:Adenolymphoma / Q000150:complications / Q000601:surgery; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D019393:Arrestin / Q000276:immunology; D001323:Autoantibodies / Q000032:analysis; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D002135:Calcium-Binding Proteins / Q000276:immunology*; D004596:Electroretinography; D004797:Enzyme-Linked Immunosorbent Assay; D005136:Eye Proteins; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D051597:Hippocalcin; D006801:Humans; D007111:Immunity, Cellular; D007136:Immunoglobulins / Q000032:analysis; D008074:Lipoproteins; D008213:Lymphocyte Activation / Q000276:immunology; D008251:Macaca; D008875:Middle Aged; D009419:Nerve Tissue Proteins; D010257:Paraneoplastic Syndromes / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D010307:Parotid Neoplasms / Q000150:complications / Q000601:surgery; D051603:Recoverin; D012160:Retina / Q000276:immunology; D012162:Retinal Degeneration / Q000276:immunology; D012164:Retinal Diseases / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D014605:Uveitis / Q000276:immunology
D000951:Antigens, Neoplasm; D019393:Arrestin; D001323:Autoantibodies; D001324:Autoantigens; D002135:Calcium-Binding Proteins; D005136:Eye Proteins; D007136:Immunoglobulins; D008074:Lipoproteins; D009419:Nerve Tissue Proteins; C496731:RCVRN protein, human; D051603:Recoverin; D051597:Hippocalcin